ITM Radiopharma
Last verified 2026-05-22. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $378.0Mattributed |
|---|---|
| Latest round | strategic, $203.0M, 2024-06-01attributed |
| Founded | 2011 |
| Headquarters | Munich, Germany |
| Industry | bio |
| Stage | series-b+ |
| Website | itm-rp.com |
ITM Radiopharma develops, manufactures, and supplies targeted radiopharmaceuticals including ITM-11 (177Lu-edotreotide) for gastroenteropancreatic neuroendocrine tumors. It treats patients with NETs, glioblastoma, osteosarcoma, and folate-receptor cancers. ITM runs its own GMP isotope production and beat Afinitor in Phase III.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-06-01 | strategic | $203.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Strategic, $203.0M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $378.0M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | itm-rp.com, read 2026-05-22 |
| Description | self-reported | itm-rp.com, read 2026-05-22 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.